All subcategories » published RCT
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline.
primary studies published RCT
Details- 2023
- Dwyer TJ
Steps Ahead: Optimising physical activity in adults with cystic fibrosis: A pilot randomised trial using wearable technology, goal setting and text message feedback.
primary studies published RCT
Details- 2023
- Curran M
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
primary studies published RCT
Details- 2023
- Uluer AZ
Embedded Specialist Palliative Care in Cystic Fibrosis: Results of a Randomized Feasibility Clinical Trial.
primary studies published RCT
Details- 2023
- Kavalieratos D
Efficacy of the Simeox(®) Airway Clearance Technology in the Homecare Treatment of Children with Clinically Stable Cystic Fibrosis: A Randomized Controlled Trial.
primary studies published RCT
Details- 2023
- Sands D
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial.
primary studies published RCT
Details- 2023
- Stahl M
A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.
primary studies published RCT
Details- 2022
- Nash EF
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
primary studies published RCT
Details- 2023
- Mayer-Hamblett N
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
primary studies published RCT
Details- 2023
- Goralski JL
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
primary studies published RCT
Details- 2023
- Wainwright C